stockrow
Saturday 7 November 2026
Export RAPP’s income statement to Excel — free account
Rapport Therapeutics, Inc.
RAPP Healthcare Biotechnology
- EPS
- −18.6%
- Free cash flow
- −64.8%
Quarter to September 2026, against a year earlier
24.48
0.76
+3.20%
Follow RAPP
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (33.33%) | (39.96%) | (28.33%) | (28.22%) |
+8 more TTM periods Free account |
|
| (31.55%) | (36.85%) | (26.83%) | (26.95%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(38.68%) | (32.60%) | (22.86%) | (23.11%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(2.53) | (2.04) | (1.71) | (2.26) | |
Free Cash Flow |
(120.78) | (96.96) | (80.71) | (88.09) | |
Capital Expenditures |
0.07 | (0.27) | (0.41) | (0.62) | |
| Other line items | |||||
Cash ROIC |
(15.36%) | (11.29%) | (8.51%) | (9.03%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.80 | 0.70 | 0.75 | 0.78 | |
Depreciation/Fixed assets |
(0.25) | 0.03 | (0.13) | (0.13) | |
Capex/Depreciation |
(0.14) | (3.75) | 1.27 | 1.63 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.53) | (2.04) | (1.70) | (2.25) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026